Earnings event puts Agios Pharmaceuticals stock in focus

Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of US$100.7 million. Revenue and loss figures also shifted for the first half.

The earnings release appears to have sharpened investor attention on Agios Pharmaceuticals, with a 7.5% 7 day share price return and a 16.1% 90 day share price return standing against a 1 year total shareholder return that is down 9.8%. Overall, short term momentum has picked up even though longer term returns remain mixed.

If you are looking beyond Agios Pharmaceuticals for other potential ideas in healthcare and biotech, this could be a helpful moment to scan 43 healthcare AI stocks.

The recent jump in Agios Pharmaceuticals shares follows stronger quarterly revenue and a smaller loss, which some investors may see as a business shift and others as sentiment chasing earnings headlines. The valuation section below tests which view holds up.

Most Popular Narrative: 26.7% Undervalued

At a last close of $32.27 versus a fair value estimate of $44.00, the most followed narrative frames Agios Pharmaceuticals as materially undervalued and heavily dependent on one key asset.

Agios's revenue growth is highly reliant on the success and expansion of PYRUKYND into new indications (thalassemia, sickle cell disease), exposing the company to significant revenue volatility if these launches or subsequent clinical/pipeline assets face setbacks, delays, or do not achieve expected uptake, negatively impacting both top-line growth and long-term earnings stability.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value leans so heavily on PYRUKYND and Aqvesme? The narrative weighs aggressive revenue expansion and potential future margin improvement against ongoing losses and a rich implied earnings multiple. The balance between rapid top line forecasts and delayed profitability is doing most of the work in that $44.00 figure.

Result: Fair Value of $44.00 (UNDERVALUED)

However, Agios Pharmaceuticals still faces concentration risk around PYRUKYND and Aqvesme, and any regulatory setbacks or safety concerns could quickly weaken the current undervaluation story.

Another View: Agios Pharmaceuticals looks expensive on sales

While one narrative pegs Agios Pharmaceuticals as 26.7% undervalued on a fair value estimate of $44.00, the picture changes when you look at simple sales multiples. The stock trades on a P/S of 19.6x, compared with 11.6x for the US Biotechs industry, 6.5x for peers, and a fair ratio of just 0.2x. That gap points to meaningful valuation risk if sentiment cools.

For a closer look at how this pricing stacks up against fundamentals, including why the current P/S sits so far above the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of risks and rewards around Agios Pharmaceuticals can feel finely balanced, so it helps to move quickly and test the data yourself. To see how those concerns and opportunities stack up side by side, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Agios Pharmaceuticals?

If Agios Pharmaceuticals has your attention, do not stop here. The next strong idea could be one screen away, so give yourself more options now.

• Target potential mispricings by checking companies that appear out of favor yet financially sound through the 51 high quality undervalued stocks.
• Strengthen your focus on resilience and capital protection by reviewing companies highlighted in the 79 resilient stocks with low risk scores.
• Spot lesser known opportunities with healthy fundamentals before the crowd by scanning the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.